Mode of death in patients with systolic heart failure.
Although the landscape of heart failure continues to rapidly evolve, and the widespread use of evidence-based pharmaceutical and device therapies has improved overall survival rates, mortality rates in heart failure patients remain high. Understanding the mode of death in heart failure is particularly important if we are to improve survival. This study reviews the evaluation of modes of death from heart failure and discusses the therapies, both pharmaceutical and device, that are useful in preventing these sequelae.
Patel
Jigar
J
Department of Cardiology, Scripps Clinic, La Jolla, California 92037, USA.
Heywood
J Thomas
JT
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D002303:Cardiac Output, Low / Q000150:complications / Q000401:mortality* / Q000628:therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002423:Cause of Death; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013599:Systole
D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents